▇▇▇▇▇▇ System. Subject to the terms and conditions of this Agreement (including, without limitation, Section 7 hereof), Rosetta hereby grants to Agilent, commencing on the date that Agilent shall elect to license the Rosetta Proposed ▇▇▇▇▇▇ Enhancements pursuant to and in accordance with Section 2.4(b), a worldwide license, co-exclusive with Rosetta, in, to and under the Rosetta Technology to develop, use, manufacture, market, offer for sale, sell and support the Rosetta Proposed ▇▇▇▇▇▇ Enhancements and any enhancements and refinements thereto with the ▇▇▇▇▇▇ System. No right is hereby granted in the Rosetta Proposed ▇▇▇▇▇▇ Enhancements in the event Agilent shall elect not to license the Rosetta * Material has been omitted pursuant to a request for confidential treatment, and such material has been filed separately with the SEC.
Appears in 2 contracts
Sources: Collaboration Agreement (Rosetta Inpharmatics Inc), Collaboration Agreement (Rosetta Inpharmatics Inc)